Freedom Broker analyst Ilya Zubkov initiated coverage of Niagen Bioscience with a Buy rating and $9 price target. The firm calls Niagen "a beneficiary of powerful secular tailwinds," including the growth of the longevity economy, rising GLP-1 adoption, and increasing consumer focus on healthspan and cellular wellness, adding that it sees significant upside from the rapid expansion of the company's ingredients segment.
